Welcome to our dedicated page for Aeon Biopharma SEC filings (Ticker: AEON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AEON Biopharma, Inc. (AEON) SEC filings page on Stock Titan aggregates the company’s official disclosures to the U.S. Securities and Exchange Commission, providing structured access to its regulatory and financial reporting. AEON is a clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA) injection as a proposed BOTOX biosimilar for therapeutic indications under the FDA’s 351(k) biosimilar pathway. Its filings offer detailed insight into this development strategy, capital structure, and governance.
Key documents include Form 8-K current reports describing material events such as the Securities Purchase Agreement for a PIPE private placement, the Exchange Agreement with Daewoong Pharmaceutical to convert senior secured convertible notes into equity, a new note due 2030, and warrants, and updates on corporate presentations made available to investors. These filings explain terms of new securities, warrant structures, conversion mechanics, and conditions tied to stockholder approval and NYSE American rules.
AEON’s definitive proxy statement on Schedule 14A details proposals for a special meeting of stockholders, including approval of the PIPE financing, the Daewoong note exchange, and amendments to the company’s incentive award plan. This proxy statement outlines how these transactions relate to funding the development and potential commercialization of ABP-450 as a biosimilar to BOTOX, and describes voting procedures and board recommendations.
Periodic filings referenced in the company’s 8-Ks, such as its Form 10-K for the fiscal year ended December 31, 2024, provide broader context on risk factors, forward-looking statements, and financial reporting policies. AEON’s 8-Ks also furnish quarterly earnings press releases, which include condensed consolidated financial statements and discussions of operating expenses, research and development spending, and changes in fair value of financial instruments.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points in lengthy documents, helping users quickly understand complex topics like convertible note exchanges, warrant anti-dilution provisions, and biosimilar regulatory milestones. Real-time updates from EDGAR ensure that new forms—whether 8-Ks, proxy statements, or annual and quarterly reports—are available promptly. Users can also track equity-related disclosures, including inducement grants and incentive plan changes, to better understand AEON’s governance and compensation practices.
AEON Biopharma, Inc. released an updated corporate investor presentation and posted it in the investor relations section of its website. The presentation, dated January 2026, is also furnished as Exhibit 99.1 and may be used by company management in future meetings about the business.
The company highlights that the presentation contains forward-looking statements and directs readers to a specific “Forward-Looking Statements” slide for important cautionary information. This disclosure is furnished under Regulation FD and is explicitly not treated as filed for liability purposes or automatically incorporated into other securities law documents unless specifically referenced.
AEON Biopharma has called a Special Meeting on January 21, 2026 to seek stockholder approval for a financing and note exchange intended to fund development and potential commercialization of ABP‑450 as a biosimilar to Botox.
Stockholders are being asked to approve a PIPE financing covering 4,616,924 shares of common stock (or pre-funded warrants) plus warrants for 6,581,829 shares and additional True-Up Warrants, which together, if exercised, are expected to raise about $11.4 million. A separate proposal would approve exchanging Daewoong’s senior secured convertible notes for a new
The proxy also seeks to increase shares under the 2023 Incentive Award Plan by 17,288,059 shares and maintain an annual share “evergreen” of up to
AEON Biopharma, Inc. is asking stockholders at a special meeting to approve a PIPE financing, an exchange of senior secured convertible notes held by Daewoong, a major increase to its equity incentive plan, and a possible adjournment of the meeting if votes are insufficient.
The PIPE second closing would sell 4,616,924 shares of common stock (or pre-funded warrants) for about $4.2 million and issue 6,581,829 five-year warrants at $1.09392 per share, plus additional True-Up Warrants, which together are expected to raise about $11.4 million including warrant exercises.
The Daewoong exchange would convert existing notes into an estimated 23.1 million shares (or pre-funded warrants), a new $1.5 million convertible note bearing 15.79% annual interest, and a warrant for 8,000,000 shares at $1.09392, making Daewoong and the PIPE investors the largest holders of AEON’s stock.
AEON is also seeking to add 17,288,059 shares to its Amended and Restated 2023 Incentive Award Plan and increase its annual “evergreen” share refresh to up to 5% of fully diluted shares, with a significant portion intended to settle existing cash-settled RSUs in stock. The company states these steps are important to fund development and potential commercialization of ABP-450 as a biosimilar to Botox and to retain key talent.
AEON Biopharma entered into an Exchange Agreement with Daewoong to swap Daewoong’s existing senior secured convertible notes into equity and a new
Daewoong will also receive warrants to purchase up to 8,000,000 shares of common stock at an exercise price of
The note can automatically convert at a 1.3x factor into equity upon a qualified equity financing of at least
AEON Biopharma, Inc. furnished a new investor Corporate Presentation under Regulation FD. The presentation, dated December 2025, has been made available in the investor relations section of AEON’s website and is also filed as Exhibit 99.1 to this report. Management may use the same materials in future meetings to explain the company’s business and outlook.
The company notes that the Corporate Presentation contains forward-looking statements and directs readers to the slide titled “Forward-Looking Statements” for important cautionary information. The materials provided in this report, including Exhibit 99.1, are being furnished rather than filed, meaning they are not automatically subject to certain liability provisions or incorporated into other securities law filings unless specifically referenced.
AEON Biopharma filed its Q3 2025 10‑Q, reporting continued operating losses and tight liquidity. The company posted a net loss of
Cash and cash equivalents were
AEON executed a 1‑for‑72 reverse stock split on February 24, 2025 and had 11,643,786 shares outstanding at September 30, 2025. In the offering, Series A and Series B warrants were issued with the exercise price reset to
AEON Biopharma furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025. The company issued a press release with details, which is included as Exhibit 99.1 to this report.
The information in this update (including Exhibit 99.1) is furnished, not filed, under the Exchange Act. AEON’s Class A common stock trades on the NYSE American under the symbol AEON.
AEON Biopharma announced a private placement and a binding note exchange term sheet. The company agreed to sell equity and warrants at a purchase price of $0.9116 per Share (or $0.9115 per pre‑funded warrant). The first closing is expected the week of November 17, 2025, with 1,964,905 Shares (or pre‑funded warrants) to be issued.
The second closing, subject to stockholder approval and consummation of the Daewoong exchange, is expected to include 4,616,924 Shares (or pre‑funded warrants) and 6,581,829 Warrants. The Warrants are cash‑exercise only at $1.09392 per share and are exercisable for five years from the second closing; pre‑funded and true‑up warrants have a $0.0001 exercise price. Warrants include full‑ratchet anti‑dilution with a floor of $0.30387, and exercises are limited by a 9.99% beneficial ownership cap (electable up to 19.99% with notice).
AEON and Daewoong signed a binding term sheet to exchange Daewoong’s existing notes for a $1.5 million note due 2030, an estimated 23,103,694 Exchange Shares (assumes a January 15, 2026 vote), and 8,000,000 Warrants at $1.09392. AEON also agreed to file a resale registration statement within 20 days of the earlier of the second closing or a specified termination.
AEON Biopharma, Inc. furnished an investor presentation as part of a corporate update. On September 8, 2025, the company made a “Corporate Presentation” available in the investor relations section of its website and attached it as Exhibit 99.1. Management may use this presentation in future meetings to discuss the company. The materials include a slide on forward-looking statements that outlines important cautionary information. The presentation and related information are furnished, not filed, so they are not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.
AEON Biopharma reported a period of transition as it pivots ABP-450 development toward a biosimilar pathway after discontinuing Phase 2 migraine trials in May 2024. The company completed a 1-for-72 reverse stock split and raised net proceeds of approximately $18.3 million from a January 2025 public offering and has an ATM program with about $49.8 million remaining. As of June 30, 2025, AEON held $8.4 million in cash and total assets of $11.7 million, against total liabilities of $27.5 million, resulting in a stockholders' deficit of $15.9 million. The company recorded a $75.6 million non‑cash loss on warrant issuance and recognized fair value movements on convertible notes and contingent consideration that materially affected reported (loss) income. Management discloses substantial doubt about the company’s ability to continue as a going concern and states additional financing will be required to advance analytical studies, a planned FDA BPD Type 2a meeting and further development of ABP-450.